<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01490684</url>
  </required_header>
  <id_info>
    <org_study_id>KAMC</org_study_id>
    <nct_id>NCT01490684</nct_id>
  </id_info>
  <brief_title>Invasive Candidiasis in Saudi ICUs</brief_title>
  <acronym>ICIP-SA</acronym>
  <official_title>Invasive Candidiasis in Critically Ill Patients in Saudi Arabia: A Prospective Cohort Study</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Hasan Al-Dorzi</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>King Fahad Medical City</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>King Abdulaziz Medical City</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Epidemiology and clinical outcomes of invasive candidiasis in critically ill patients in
      Saudi Arabia is not well studied. This observational study objectives include to determine
      the epidemiology, risk factors and outcomes of invasive Candida infection in critically ill
      patients in Saudi Arabia.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>August 2012</start_date>
  <completion_date type="Actual">May 2016</completion_date>
  <primary_completion_date type="Actual">May 2016</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Hospital Mortality</measure>
    <time_frame>Patients will be followed while in the ICU and the vital status at the time of discharge from the ICU will be noted. The expected stay in the ICU is 10 days on average.</time_frame>
    <description>For patients staying in the ICU for long periods, hospital mortality will be censored at 180 days after entry into the study.That is patient staying alive in the hospital more than 180 days will be considered alive.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>ICU Mortality</measure>
    <time_frame>patients will be followed until discharge from the hospital and vital status at discharge from the hospital will be noted (expected hospital stay is 5 weeks). Hopsital mortality will be censored at 180 days after entry into the study.</time_frame>
    <description>If patients are still alive in the ICU at 180 days after entring the sudy, they will be considered ICU survivors.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Duration of Mechanical Ventilation</measure>
    <time_frame>date of extubtation minus date of intubation</time_frame>
    <description>If multiple intubations in the same admission, then the durations of mechanical ventilation will be added.This will be assessed for up to 180 days of stay in the ICU.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Length of Stay in the ICU</measure>
    <time_frame>date of discharge from ICU minus date of admission to ICU</time_frame>
    <description>Patients will be followed for up to 180 days.Patinets alive in the ICU beyond 180 days of stay will have an ICU length of stay of 180 days.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Length of Stay in the Hospital</measure>
    <time_frame>date of discharge from hospital minus date of admission to hospital</time_frame>
    <description>Patients will be followed for up to 180 days.Patinets alive in the hospital beyond 180 days of stay will have a hospital length of stay of 180 days.</description>
  </secondary_outcome>
  <enrollment type="Actual">162</enrollment>
  <condition>Invasive Candidiasis</condition>
  <eligibility>
    <study_pop>
      <textblock>
        All adult patients (&gt; 18 years) admitted to the ICUs of these centers will be evaluated for
        the occurrence of Candida infection and followed to discharge or death in ICU. The duration
        of the study will be 12 months. Also patients who had invasive candidiasis within 72 hours
        of ICU admission will be included.
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  adult patients (&gt; 18 years)

          -  develop invasive candidiasis as per prespecified definitions during ICU stay

          -  In addition, patients who had invasive candidiasis within 72 hours of ICU admission
             will be included

        Exclusion Criteria:

          -  Diagnosis of invasive candidiasis (definite or probable) more than 72 hours before ICU
             admission.

          -  Diagnosis of invasive candidiasis (definite or probable) within 72 hours of ICU
             admission, but the admission to ICU for an unrelated reason.

          -  Readmission to the ICU during the same hospitalization with invasive candidiasis
             occurring during one of the previous admissions.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Hasan Al-Dorzi, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>King Abdulaziz Medical City</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>King Abdulaziz Medical City</name>
      <address>
        <city>Riyadh</city>
        <country>Saudi Arabia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>King Fahad Medical City</name>
      <address>
        <city>Riyadh</city>
        <country>Saudi Arabia</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Saudi Arabia</country>
  </location_countries>
  <verification_date>November 2017</verification_date>
  <study_first_submitted>December 2, 2011</study_first_submitted>
  <study_first_submitted_qc>December 10, 2011</study_first_submitted_qc>
  <study_first_posted type="Estimate">December 13, 2011</study_first_posted>
  <results_first_submitted>November 30, 2017</results_first_submitted>
  <results_first_submitted_qc>November 30, 2017</results_first_submitted_qc>
  <results_first_posted type="Actual">August 24, 2018</results_first_posted>
  <last_update_submitted>November 30, 2017</last_update_submitted>
  <last_update_submitted_qc>November 30, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">August 24, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor-Investigator</responsible_party_type>
    <investigator_affiliation>King Abdulaziz Medical City</investigator_affiliation>
    <investigator_full_name>Hasan Al-Dorzi</investigator_full_name>
    <investigator_title>Consultant, Intensive Care Department</investigator_title>
  </responsible_party>
  <keyword>candidiasis</keyword>
  <keyword>critically ill</keyword>
  <keyword>outcomes</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Candidiasis</mesh_term>
    <mesh_term>Candidiasis, Invasive</mesh_term>
  </condition_browse>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>The Whole Cohort</title>
          <description>The whole cohort included one group of patients with invasive candidiasis as per the Inclusion and Exclusion Criteria.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="162"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="162"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>The Whole Cohort</title>
          <description>The whole cohort included one group of patients with invasive candidiasis as per the Inclusion and Exclusion Criteria.</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="162"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="58.4" spread="18.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="77"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="85"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Saudi Arabia</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="162"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Hospital Mortality</title>
        <description>For patients staying in the ICU for long periods, hospital mortality will be censored at 180 days after entry into the study.That is patient staying alive in the hospital more than 180 days will be considered alive.</description>
        <time_frame>Patients will be followed while in the ICU and the vital status at the time of discharge from the ICU will be noted. The expected stay in the ICU is 10 days on average.</time_frame>
        <group_list>
          <group group_id="O1">
            <title>The Whole Cohort</title>
            <description>The whole cohort included one group of patients with invasive candidiasis as per the Inclusion and Exclusion Criteria.</description>
          </group>
        </group_list>
        <measure>
          <title>Hospital Mortality</title>
          <description>For patients staying in the ICU for long periods, hospital mortality will be censored at 180 days after entry into the study.That is patient staying alive in the hospital more than 180 days will be considered alive.</description>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="162"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="95"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>ICU Mortality</title>
        <description>If patients are still alive in the ICU at 180 days after entring the sudy, they will be considered ICU survivors.</description>
        <time_frame>patients will be followed until discharge from the hospital and vital status at discharge from the hospital will be noted (expected hospital stay is 5 weeks). Hopsital mortality will be censored at 180 days after entry into the study.</time_frame>
        <group_list>
          <group group_id="O1">
            <title>The Whole Cohort</title>
            <description>The whole cohort included one group of patients with invasive candidiasis as per the Inclusion and Exclusion Criteria.</description>
          </group>
        </group_list>
        <measure>
          <title>ICU Mortality</title>
          <description>If patients are still alive in the ICU at 180 days after entring the sudy, they will be considered ICU survivors.</description>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="162"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="83"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Duration of Mechanical Ventilation</title>
        <description>If multiple intubations in the same admission, then the durations of mechanical ventilation will be added.This will be assessed for up to 180 days of stay in the ICU.</description>
        <time_frame>date of extubtation minus date of intubation</time_frame>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Length of Stay in the ICU</title>
        <description>Patients will be followed for up to 180 days.Patinets alive in the ICU beyond 180 days of stay will have an ICU length of stay of 180 days.</description>
        <time_frame>date of discharge from ICU minus date of admission to ICU</time_frame>
        <group_list>
          <group group_id="O1">
            <title>The Whole Cohort</title>
            <description>The whole cohort included one group of patients with invasive candidiasis as per the Inclusion and Exclusion Criteria.</description>
          </group>
        </group_list>
        <measure>
          <title>Length of Stay in the ICU</title>
          <description>Patients will be followed for up to 180 days.Patinets alive in the ICU beyond 180 days of stay will have an ICU length of stay of 180 days.</description>
          <units>days</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="162"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="42.4" spread="54.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Length of Stay in the Hospital</title>
        <description>Patients will be followed for up to 180 days.Patinets alive in the hospital beyond 180 days of stay will have a hospital length of stay of 180 days.</description>
        <time_frame>date of discharge from hospital minus date of admission to hospital</time_frame>
        <group_list>
          <group group_id="O1">
            <title>The Whole Cohort</title>
            <description>The whole cohort included one group of patients with invasive candidiasis as per the Inclusion and Exclusion Criteria.</description>
          </group>
        </group_list>
        <measure>
          <title>Length of Stay in the Hospital</title>
          <description>Patients will be followed for up to 180 days.Patinets alive in the hospital beyond 180 days of stay will have a hospital length of stay of 180 days.</description>
          <units>days</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="162"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="88.8" spread="87.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <group_list>
        <group group_id="E1">
          <title>The Whole Cohort</title>
          <description>The whole cohort included one group of patients with invasive candidiasis as per the Inclusion and Exclusion Criteria.</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, all-cause mortality</sub_title>
                <counts group_id="E1" subjects_affected="95" subjects_at_risk="162"/>
              </event>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="162"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="162"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Dr Hasan Al-Dorzi</name_or_title>
      <organization>King Abdulaziz Medical City</organization>
      <phone>966535888632</phone>
      <email>aldorzih@yahoo.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

